comparemela.com
Latest Breaking News On - Gatekeeper pharmaceuticals - Page 1 : comparemela.com
Adding Chemotherapy to Osimertinib Improves PFS in EGFR-Mutant, Advanced NSCLC
Osimertinib and chemotherapy is more effective than osimertinib alone as first-line treatment for EGFR-mutant, advanced NSCLC, phase 3 data suggest.
Boston
Massachusetts
United-states
Dana-farber-cancer-institute
Daiichi-sankyo
Eli-lilly
Roche-genentech
Astellas-pharmaceuticals
Gatekeeper-pharmaceuticals
Boehringer-ingelheim
Pfizer
Novartis
Adagrasib Induces 68% ORR in Subset of Patients With KRAS G12C–Mutated NSCLC
Adagrasib induced high overall response rates in patients with KRAS G12C–mutated non–small cell lung cancer who achieved at least 90% mutation allele frequency clearance.
Copenhagen
Køavn
Denmark
Switzerland
Geneva
Genè
Monte-rosa
Daiichi-sankyo
Adagrasib-krazati
Roche-genentech
Eli-lilly
Lowe-center
vimarsana © 2020. All Rights Reserved.